Latest Breaking News On - Erica warlick - Page 1 : comparemela.com

GT Biopharma Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE™, a Novel NK Cell Therapeutic Cancer Treatment

Anthony J. Cataldo, GT Biopharma s Chairman and Chief Executive Officer, commented: It is exciting to announce the addition of a second clinical trial site for our Phase I/II program of our novel GTB-3550 TriKE™ program. With this progress, we are closer to bringing our disruptive and target-directed NK cell engager approach to patients in need. We are grateful to the valiant patients and their families, as we continue to progress this initial indication trial of our first-in-class NK cell protein biologic cancer therapy. GTB-3550 TriKE™ is being evaluated in patients age 18 and older with CD33+ malignancies (primary induction failure or relapsed acute myeloid leukemia [AML] with failure of one reinduction attempt, or high-risk myelodysplastic syndromes [MDS] progressed on two lines of therapy). The primary endpoint is to identify the maximum tolerated dose and safety of GTB-3550 TriKE™ therapy. Correlative objectives include the number, phenotype, activation status and func

United statesJulie seidelErica warlickSusan roushAnthonyj cataldoVara ganesh nadimintiJefferys millerDavid castanedaBeverly hillsPrnewswire gt biopharma incStern investor relations incSource gt biopharma incMadison carbone cancer centerExchange commissionUniversity of wisconsinAmerican society of hematology

GT Biopharma Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE™, a Novel NK Cell Therapeutic Cancer Treatment

Share this article Share this article BEVERLY HILLS, Calif., March 4, 2021 /PRNewswire/ GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on the development and commercialization of its disruptive, target-directed Natural Killer (NK) cell engager immunotherapy protein biologic platform technology: TriKE™ for cancer and infectious diseases, today announced the addition of a new clinical trial site for its ongoing GTB-3550 TriKE™ multicenter Phase I/II trial (ClinicalTrials.gov NCT03214666). The University of Wisconsin – Madison Carbone Cancer Center will serve as the second site for this program, with Kalyan Vara Ganesh Nadiminti M.D., UW Assistant Professor in Hematology, Oncology and Palliative Care, serving as lead investigator. Dr. Nadiminti will be working closely with Jeffery S. Miller, M.D., GT Biopharma s Consulting Chief Medical Officer and developer of TriKE™ and the trial design, and Erica Warlick, M.D., Principal Investigato

United statesJefferys millerVara ganesh nadimintiAnthonyj cataldoErica warlickDavid castanedaBeverly hillsSusan roushStern investor relations incSource gt biopharma incMadison carbone cancer centerExchange commissionAmerican society of hematologyUniversity of wisconsinUniversity of minnesotaGt biopharma inc

GT Biopharma : Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patie

GT Biopharma : Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patie
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesAnthony cataldoErica warlickBeverly hillsExchange commissionAmerican society of hematologyNational cancer instituteAmerican society of hematology annual meetingUniversity of minnesotaGt biopharma incReduces bone marrow blast levelsResults presentedAmerican societyHematology annual meetingPrincipal investigatorOral session

GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550 TriKE™ REDUCES CANCER CELLS BY 61 7% FOR A HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) PATIENT

Published: Dec 21, 2020 BEVERLY HILLS, Calif, Dec. 21, 2020 /PRNewswire/ GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company s proprietary NK cell engager (TriKE™) technology platform is pleased to announce the presentation of additional interim data results for the Company s lead therapeutic candidate, GTB-3550, for the treatment of high-risk myelodysplastic syndromes (HR-MDS). Erica Warlick, M.D, Principal Investigator for the GTB-3550 clinical trial, presented additional clinical data results with the treatment with HR-MDS patient #7 of its TriKE™ GTB-3550 during the Q&A session following her presentation at the 62 nd American Society of Hematology (ASH) Annual Meeting and Exposition. Dr. Warlick s HR-MDS patient presentation can be viewed on the GT Biopharma web site at https://ir.gtbiopharma.com/presentations.

United statesAnthony cataldoErica warlickBeverly hillsExchange commissionAmerican society of hematologyPrnewswire gt biopharma incCompany codesSource gt biopharma incUniversity of minnesotaGt biopharma incPrincipal investigatorAmerican societyAnnual meetingChief executive officerPotent native